Oncolytics Biotech Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ONCY Nasdaq 2836 oncolyticsbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Oncolytics Biotech Inc.

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - Jan 12th, 2026 7:00 am
Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances - Jan 12th, 2026 2:23 am
Oncolytics outlines strategic rationale for proposal to change jurisdiction - Jan 10th, 2026 7:05 am
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - Jan 9th, 2026 7:00 am
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - Jan 8th, 2026 7:00 am
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Jan 7th, 2026 7:00 am
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - Dec 16th, 2025 7:00 am
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada - Dec 9th, 2025 4:00 pm
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Dec 3rd, 2025 7:35 am
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - Nov 20th, 2025 2:05 pm
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy - Nov 19th, 2025 10:00 am
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - Nov 19th, 2025 7:00 am
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy - Nov 4th, 2025 6:00 am
Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care - Oct 28th, 2025 5:30 am
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada - Oct 20th, 2025 7:00 am
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study - Sep 29th, 2025 6:30 am
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion - Sep 16th, 2025 5:00 am
Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer - Sep 8th, 2025 6:28 am
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions - Sep 8th, 2025 5:00 am
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors - Sep 2nd, 2025 7:10 am